United States Hereditary Angioedema Therapeutics Market

1. United States Hereditary Angioedema Therapeutics Market: Size, Share, and In-Depth Competitive Analysis Toward 2028 - A TechSci Research Comprehensive Study In recent years, the United States has witnessed significant advancements in the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by recurrent, severe swelling in various parts of the body. According to a comprehensive report by TechSci Research titled “Hereditary Angioedema Therapeutics Market – United States Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the United States Hereditary Angioedema Therapeutics Market stood at USD 846.80 million in 2022 and is anticipated to grow with a CAGR of 7.12% in the forecast period from 2024 to 2028. Understanding Hereditary Angioedema Hereditary Angioedema is a complex condition that poses significant challenges for patients and healthcare providers. The swelling associated with HAE can occur in various parts of the body, including the face, hands, feet, and gastrointestinal tract, leading to discomfort, pain, and potentially life- threatening complications. Managing HAE requires a multi-faceted approach, encompassing both acute treatment of attacks and prophylactic measures to prevent future episodes. Browse over XX market data Figures spread throughXX Pages and an in-depth TOC on"United States Hereditary Angioedema Therapeutics Market.” –

2. https://www.techsciresearch.com/report/united-states-hereditary-angioedema-therapeutics-https://www.techsciresearch.com/report/united-states-hereditary-angioedema-therapeutics- market/21032.html Driving Factors of the HAE Therapeutics Market One of the primary drivers of the HAE therapeutics market in the United States is the increased awareness of the condition among both healthcare professionals and the general public. As knowledge about HAE has spread, more patients are being accurately diagnosed. Improved diagnosis ensures that patients receive the appropriate treatment early in their disease journey, reducing the risk of severe complications. This has not only improved the quality of life for HAE patients but has also expanded the patient population in need of treatment. Evolution of Treatment Options Traditionally, HAE management relied on C1 inhibitor replacement therapy and bradykinin receptor antagonists. However, these traditional treatments had limitations, such as the need for intravenous administration and frequent injections. Recent innovations in drug development have led to the approval of subcutaneous and oral therapies. These novel treatments offer convenience, ease of use, and reduced side effects, enhancing the patient experience and providing more options to healthcare providers. FDA Approvals and Breakthrough Therapies The United States Food and Drug Administration (FDA) has been proactive in evaluating and approving breakthrough therapies for HAE. Several medications have received FDA approval, including prophylactic and acute treatment options. For example, drugs like lanadelumab (Takhzyro) have transformed HAE management, offering long-lasting prevention of attacks and significantly reducing the frequency of administration compared to previous treatments. This has led to better disease control, reduced hospitalizations, and improved patient outcomes. Patient-Centered Approach The HAE therapeutics market has evolved to become increasingly patient-centered. Pharmaceutical companies and healthcare providers are recognizing the unique needs of HAE patients and tailoring treatments to provide a better quality of life. This approach encompasses the development of more convenient therapies and includes patient support programs, educational resources, and advocacy initiatives to empower patients and their families. These efforts ensure that patients are well-informed and actively engaged in managing their condition, which is essential for long-term success. Segment Analysis The United States Hereditary Angioedema Therapeutics Market is segmented into Ingredient Treatment, Route of Administration, End-use, Regional Distribution, And Company. Based on Treatment: C1-esterase inhibitor emerged as the dominant segment in the United States market for United States Hereditary Angioedema Therapeutics Market in 2022. C1-esterase inhibitors can be used both on-demand to treat acute attacks and as prophylactic therapy to prevent attacks. The dual functionality makes them suitable for addressing immediate relief and long-term disease control, catering to the needs of both newly diagnosed and established HAE patients. Based on End-use: Prophylaxis emerged as the dominant segment in the United States market for United States Hereditary Angioedema Therapeutics Market in 2022. Prophylaxis involves the regular

3. use of HAE therapies to prevent attacks before they occur. This approach is highly effective in minimizing the frequency and severity of HAE attacks, thus improving the overall quality of life for patients. Regional Analysis Mid-West emerged as the dominant player in the United States Hereditary Angioedema Therapeutics Market in 2022, holding the largest market share. The Midwest region boasts a well-developed and extensive healthcare infrastructure, making it a hub for advanced medical research and patient care. Several renowned research institutions and pharmaceutical companies with a focus on rare diseases are located in the Midwest. These institutions have been at the forefront of HAE research and have played a significant role in developing innovative therapies for the condition. Their research efforts have contributed to the availability of advanced HAE treatments. Benefits of the Research Report • Insightful Market Analysis: The report provides a comprehensive analysis of the United States Hereditary Angioedema Therapeutics Market, including market size, growth trends, and competitive landscape. • Strategic Planning: For pharmaceutical companies, healthcare providers, and investors, the report offers valuable insights for strategic planning and decision-making. • Understanding Market Dynamics: By examining key drivers, challenges, and opportunities, the report helps stakeholders understand the dynamic nature of the HAE therapeutics market. • Identifying Growth Opportunities: With projections for market growth and emerging trends, the report assists stakeholders in identifying lucrative opportunities for investment and expansion. • Competitive Benchmarking: Through detailed competitive analysis, the report enables companies to benchmark their performance against industry peers and identify areas for improvement. The United States Hereditary Angioedema Therapeutics Market is poised for significant growth in the coming years, driven by advancements in treatment options, increased awareness of the condition, and a patient-centered approach to care. With the support of innovative therapies and comprehensive research efforts, the outlook for HAE patients is increasingly optimistic, promising improved outcomes and a better quality of life. Major companies operating in United StatesHereditary Angioedema Therapeutics Market are: • BioCryst Pharmaceuticals, Inc. • Ionis Pharmaceuticals • CSL Behring • Attune Pharmaceuticals • Adverum Biotechnologies, Inc. • KalVista Pharmaceuticals, Inc. • Takeda Pharmaceutical Company Limited

4. • Pharming Healthcare Inc. • Sanofi AG • Cipla Inc Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=21032 Customers can also request for 10% free customization on this report. “The United States Hereditary Angioedema Therapeutics (NGS) market is poised for significant growth in the coming years. ongoing research and development efforts are continuously yielding innovative therapies that are more effective and patient friendly. Advanced monoclonal antibodies, oral medications, and prophylactic treatments provide HAE patients with an array of options for disease management. Moreover, increased awareness, early diagnosis, and genetic testing are improving the identification of HAE cases, ensuring timely intervention and personalized treatment plans. The patient-centered approach is becoming more prevalent, fostering a culture of empowerment and self- management among HAE individuals.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm. “United States Hereditary Angioedema Therapeutics Market Segmented By Treatment (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Route of Administration (Intravenous, Subcutaneous, Oral), By End-use (Prophylaxis, On-demand) Region and Competition, Opportunity, and Forecast, 2018-2028”, has evaluated the future growth potential of United States Hereditary Angioedema Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Hereditary Angioedema Therapeutics Market. Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=21032 Recently Published Reports: Viral Clearance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast Life Science and Chemical Instrumentation Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Targeted Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast Contact Techsci Research US - Techsci Research LLC

5. 420 Lexington Avenue, Suite 300, New York, United States- 10170 Tel:+13322586602 Email:sales@techsciresearch.com Web: https://www.techsciresearch.com/